These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37880055)

  • 1. Safety and Efficacy of Direct Oral Anticoagulant in Addition to Antiplatelet Therapy After Acute Coronary Syndrome: A Systemic Review and Meta-analysis of 53,869 Patients.
    Alharbi A; Mhanna M; Alyosif M; Pena C; Jabr A; Alsughayer A; Alfatlawi H; Safi M; Aldhafeeri A; Patel N; Khuder S; Eltahawy E
    Clin Ther; 2024 Jan; 46(1):e1-e6. PubMed ID: 37880055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention After Acute Coronary Syndromes: A Systematic Review and Meta-analysis.
    Chiarito M; Cao D; Cannata F; Godino C; Lodigiani C; Ferrante G; Lopes RD; Alexander JH; Reimers B; Condorelli G; Stefanini GG
    JAMA Cardiol; 2018 Mar; 3(3):234-241. PubMed ID: 29417147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual therapy with oral anticoagulation and single antiplatelet agent versus monotherapy with oral anticoagulation alone in patients with atrial fibrillation and stable ischemic heart disease: a systematic review and meta-analysis.
    Shakir A; Khan A; Agarwal S; Clifton S; Reese J; Munir MB; Nasir UB; Khan SU; Gopinathannair R; DeSimone CV; Deshmukh A; Jackman WM; Stavrakis S; Asad ZUA
    J Interv Card Electrophysiol; 2023 Mar; 66(2):493-506. PubMed ID: 36085242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials.
    Li J; Wang Q; Wu C; Qu X; Zhang L; He X; Ma S; Qiu M; Wang X
    Cardiology; 2023; 148(4):363-373. PubMed ID: 37094558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk and benefit of direct oral anticoagulants or PAR-1 antagonists in addition to antiplatelet therapy in patients with acute coronary syndrome.
    Gao F; Shen H; Wang ZJ; Yang SW; Liu XL; Zhou YJ
    Thromb Res; 2015 Aug; 136(2):243-9. PubMed ID: 26037286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients.
    Galli M; Andreotti F; Porto I; Crea F
    Europace; 2020 Apr; 22(4):538-546. PubMed ID: 31942971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review.
    Lane DA; Raichand S; Moore D; Connock M; Fry-Smith A; Fitzmaurice DA;
    Health Technol Assess; 2013 Jul; 17(30):1-188. PubMed ID: 23880057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: A meta-analysis of observational studies.
    Bavishi C; Koulova A; Bangalore S; Sawant A; Chatterjee S; Ather S; Valencia J; Sarafoff N; Rubboli A; Airaksinen JK; Lip GY; Tamis-Holland JE
    Catheter Cardiovasc Interv; 2016 Jul; 88(1):E12-22. PubMed ID: 26354765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis.
    Oldgren J; Wallentin L; Alexander JH; James S; Jönelid B; Steg G; Sundström J
    Eur Heart J; 2013 Jun; 34(22):1670-80. PubMed ID: 23470494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis.
    Al Said S; Kaier K; Sumaya W; Alsaid D; Duerschmied D; Storey RF; Gibson CM; Westermann D; Alabed S
    Cochrane Database Syst Rev; 2024 Jan; 1(1):CD014678. PubMed ID: 38264795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular and major bleeding outcomes with antiplatelet and direct oral anticoagulants in patients with acute coronary syndrome and atrial fibrillation: A population-based analysis.
    Dawwas GK; Barnes GD; Dietrich E; Cuker A; Leonard CE; Genuardi MV; Lewis JD
    Am Heart J; 2021 Dec; 242():71-81. PubMed ID: 34450051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term antiplatelet versus anticoagulant therapy after left atrial appendage closure: a systematic review and meta-analysis.
    Zhou Q; Liu X; Gu ZC; Yang X; Huang XH; Wu YZ; Tao YY; Wei M
    J Thromb Thrombolysis; 2024 Feb; 57(2):194-203. PubMed ID: 38180590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials.
    Galli M; Capodanno D; Benenati S; D'Amario D; Crea F; Andreotti F; Angiolillo DJ
    Eur Heart J Cardiovasc Pharmacother; 2022 Aug; 8(5):519-528. PubMed ID: 34146091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndromes: a Review.
    Khalil P; Kabbach G
    Curr Cardiol Rep; 2019 Jan; 21(1):5. PubMed ID: 30689068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-Antithrombotic Therapy With DOACs After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.
    Shurrab M; Danon A; Alnasser S; Glover B; Kaoutskaia A; Henderson M; Newman D; Crystal E; Ko D
    Can J Cardiol; 2020 Jan; 36(1):135-142. PubMed ID: 31874747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct Oral Anticoagulants vs. Vitamin K Antagonists in Atrial Fibrillation Patients at Risk of Falling: A Meta-Analysis.
    Gao X; Huang D; Hu Y; Chen Y; Zhang H; Liu F; Luo J
    Front Cardiovasc Med; 2022; 9():833329. PubMed ID: 35615562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and meta-analysis.
    Valeriani E; Porreca E; Weitz JI; Schulman S; Candeloro M; Di Nisio M
    J Thromb Haemost; 2020 Jul; 18(7):1661-1671. PubMed ID: 32202042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in Antiplatelet and Anticoagulant Therapies for NSTE-ACS.
    Badjatiya A; Rao SV
    Curr Cardiol Rep; 2019 Jan; 21(1):3. PubMed ID: 30637536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events.
    Lemesle G; Ducrocq G; Elbez Y; Van Belle E; Goto S; Cannon CP; Bauters C; Bhatt DL; Steg PG;
    Clin Cardiol; 2017 Oct; 40(10):932-939. PubMed ID: 28692742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.